“a nonsignificant trend”

A separate update of the SMAC meta-analysis including this EORTC study with a total of 2170 patients, presented by O’Connor et al, showed a benefit of adjuvant chemotherapy for disease-free and overall survival after 5 years, but only a nonsignificant trend toward improved survival after 10 years (OR 0.87, P = 0.12). 7 A pooled analysis of individual patient data from the two largest adjuvant trials conducted by EORTC 6 , 8 using doxorubicin- and ifosfamide-based chemotherapy was also presented the same year and did not show a survival advantage for p

Subgroups and secondary endpoints There was no evidence of effect modification by BCLC stage (interaction p = 0.28) or HBV status (interaction p = 0.34), and only a nonsignificant trend toward stronger associations in non-curative versus curative therapy settings (interaction p = 0.12) (Table 3 ).

However, women who received ASA showed a nonsignificant trend toward achieving a live birth after LIT ( P =0.12; Table 3 ).

Among those with an abnormal response to acetylcholine provocation, there was a nonsignificant trend toward less epicardial spasm (28% with vs 41% without, P = .12), and a trend toward more microvascular spasm (72% with and 59% without, P = .36) that did not reach statistical significance.

Cardiorespiratory Fitness There was a nonsignificant trend for both groups to improve their cardiorespiratory fitness, denoted by a suggested decrease in mean BPM over time (time effect P =.12).

In the liver-specific Mc3r knockout mice, no significant total body composition changes and a nonsignificant trend towards worsened ITT AUCg (Alb-Cre+/+: n=8, 12795 ± 943; LoxP+/+, Alb-Cre+/+: n=8, 14893 ± 855 min*mg/dL, p=0.12) were observed; however, GTT AUCg was higher (Alb-Cre+/+: n=8, 19691 ± 1351; LoxP+/+, Alb-Cre+/+: n=9, 24450 ± 1657 min*mg/dL, p=0. 042), and there was an increase in liver weight (Alb-Cre+/+: n=8, 1. 025 ± 0. 09 g; LoxP+/+, Alb-Cre+/+: n=9, 1.44 ± 0. 09 g, p=0. 0007).

Grade I tumors exhibited a nonsignificant trend toward reduced survival in the high-expression group (HR = 2.01, 95% CI: 0.82–4.89, p = 0.12) ( Fig. 4 A), while significant survival differences were observed in grade II (HR = 1.63, 95% CI: 1.09–2.44, p = 0.017) and grade III tumors (HR = 1.97, 95% CI: 1.15–3.37, p = 0.012) ( Fig. 4 B,C).

In our cohort of AS patients with disease ≥7.5 cm, there was a nonsignificant trend toward improved LC with consolidative RT at 3 years (100% vs 53.8%; P = .121).

The 2013 strain exhibited a nonsignificant trend toward higher expression of multiple Opa proteins than the original UK strain (23 of 51 isolates [45%] vs 7 of 30 [23%]; P = .1219; Figure 3D ).

Fecal incontinence occurred in 1,215 patients (0.8%) and was significantly associated with nicotine-only use (aOR 1.20, 95% CI 1.06–1.37, p = 0.006) and concurrent use (aOR 1.58, 95% CI 1.05–2.37, p = 0.028), with a nonsignificant trend for cannabis-only use (aOR 1.75, 95% CI 0.86–3.56, p = 0.122).

Low PR (<20%) showed a nonsignificant trend (OR 1.96, 95% CI 0.83–4.61, p = 0.122).

In this analysis, external profiling showed a nonsignificant trend towards lower implementation rates (OR 0.62, 95% CI 0.33–1.12, p = 0.122).

Moreover, a significant interaction between infarct size and housing was observed for Iba1, with a nonsignificant trend also present for Gal3 (Supporting Information S1: Table 2 : infarct_area vs. cc_gal3, infarct_area:group p = 0.123).

There was also a nonsignificant trend to higher rates of macrosomia in the pandemic-exposed cohort compared with the pre-pandemic cohort (8.55% vs. 7.99% respectively, p = 0.124).

Tacrolimus formulation (IR vs PR) showed a nonsignificant trend toward a higher risk (OR = 3.43, 95% CI: 0.71–16.46, p = 0.124).

Deeks’ tests for publication bias demonstrated a nonsignificant trend toward small‐study effects for Angio‐FFR (bias estimate = ‐7.37 ± 4.74, p = 0.124), and no detectable bias was observed for ICI‐FFR (bias estimate = 3.04 ± 4.78, p = 0.533). 3.4 Sensitivity and Specificity of Computational FFR According to the ANOVA model, IVUS‐FFR had the highest ASEN of 0.92 (0.91, 0.94), and Angio‐FFR and OCT‐FFR performed similarly with the ASEN of 0.84 (0.84, 0.85) and 0.82 (0.79, 0.84), respectively.

Result(s) There was a nonsignificant trend toward a lower risk of intrauterine growth restriction (4% vs. 16%, P = .124) and preterm delivery (6% vs. 15%, P = .343) among patients who lost at least some weight.

In multivariable Cox regression analysis adjusted for age, tumor size, lymph node status, histologic grade, and Ki-67, high AMPKβ protein expression was significantly associated with poorer DFS (HR, 2.932; 95% CI, 1.009–8.519; p = 0.048), while only a nonsignificant trend toward poorer DDFS was observed (HR, 2.645; 95% CI, 0.765–9.139; p = 0.124) in patients with early TNBC ( Supplementary Table S2 ).

In contrast, posterior mPFC shows a nonsignificant trend in the opposite direction (r = 0.24; p = 0.126).

In those cases with ICH, there was a nonsignificant trend to a higher history of hypertension (50.0% vs. 23.9%, p value = 0.126), and a significant increase of anticoagulant use (20.0% vs. 1.9%, p value = 0.006), but not of antiplatelet agents.

Lower work-loop cross-bridge energy expenditure in hypertrophic rats was consistent with a nonsignificant trend for lower peak shortening heat in this group ( Fig. 6 E ; P = 0.1272).

An exploratory interaction term (KD × ASM burden) showed a nonsignificant trend ( p = 0.128), possibly indicating enhanced KD efficacy in more refractory cases.

After Bonferroni correction, in patients who used immunotherapy in the first-line setting, second-line A nonsignificant trend toward better ORR and DCR was observed with I + A treatment versus chemotherapy alone (ORR: 24.3% vs. 10.0%, P = 0.128; DCR: 81.1% vs. 56.7%, P = 0.030) (Fig. 3 E and F).

In men, no significant associations were observed for these conditions, although there was a nonsignificant trend toward a higher risk of type 2 diabetes [RR = 1.70, 95% CI: (0.86 to 3.40), p = 0.129].

Similarly, a nonsignificant trend toward a higher 10‐year risk of fatal CHD in highlanders than in lowlanders (12.5% vs. 14.9%, p = 0.1296) was observed.